Abstract
Daunorubicin, a component of the four-drug induction chemotherapy regimen for de novo pediatric high-risk acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy), was unavailable in 2011 due to a national drug shortage. During this time, our institution substituted mitoxantrone 6.25 mg/m(2) for daunorubicin 25 mg/m(2) on induction Days 1, 8, 15, and 22. While mitoxantrone has been shown to be effective for relapsed ALL, it has not been studied in de novo pediatric ALL/LLy. We conducted a retrospective cohort study of newly diagnosed patients with ALL or LLy at our institution 1/2009-4/2013 to compare induction toxicity and response of patients treated with mitoxantrone versus daunorubicin. Eleven patients received mitoxantrone, 121 patients received daunorubicin. Induction toxicities including deaths, intensive care unit admissions, fever, bacteremia, and invasive fungal disease were similar for the two groups. Mean number of days hospitalized during induction was also similar (mitoxantrone 9.7 days vs. daunorubicin 11.2 days, P = 0.60). Minimal residual disease prevalence at the end of induction was not significantly different (mitoxantrone 33.3% vs. daunorubicin 23.0%, P = 0.44). The only significant difference be...Continue Reading
References
Jan 1, 1977·Medical and Pediatric Oncology·S E SallanN Jaffe
Aug 1, 1991·Investigational New Drugs·M L GrahamR W Wilkerson
Jan 1, 1989·Medical and Pediatric Oncology·J D BuckleyG D Hammond
Jan 1, 1985·Investigational New Drugs·G Falkson, B J Coetzer
Jan 1, 1982·Cancer Chemotherapy and Pharmacology·S Fujimoto, M Ogawa
Jan 1, 1994·Medical and Pediatric Oncology·R J WellsM S Cairo
Mar 30, 2000·Leukemia Research·P J RosenF R Appelbaum
May 8, 2000·Medical and Pediatric Oncology·A M LeaheyB J Lange
Mar 11, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E C van DalenL C M Kremer
Sep 24, 2004·Pediatric Blood & Cancer·Blythe ThomsonDouglas S Hawkins
Jan 12, 2008·Pediatrics·Sadhna M ShankarUNKNOWN Cardiovascular Disease Task Force of the Children's Oncology Group
Dec 7, 2010·Lancet·Catriona ParkerVaskar Saha
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen P HungerWilliam L Carroll
Sep 6, 2012·Pediatric Blood & Cancer·Gabriele EscherichUNKNOWN CoALL study group
Sep 28, 2012·Pediatric Blood & Cancer·Rebecca A GardnerDouglas S Hawkins
Dec 21, 2012·Pediatric Blood & Cancer·Stephen P HungerUNKNOWN COG Acute Lymphoblastic Leukemia Committee
Feb 7, 2013·Leukemia & Lymphoma·Samit PatelBruno C Medeiros
Citations
Jan 30, 2015·Leukemia & Lymphoma·José Carlos Jaime-PerezDavid Gómez-Almaguer
Dec 10, 2015·Naunyn-Schmiedeberg's Archives of Pharmacology·Veronica FerrucciMassimo Zollo
Sep 11, 2018·Health Services Research·Nancy G HedlundLisa M Powell
May 6, 2019·PloS One·Jonathan Minh PhuongRebekah Moles